ABSTRACT

Background: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a rare but potentially life-threatening severe cutaneous adverse reaction characterized by extensive skin eruption, hematologic abnormalities, and multiorgan involvement. Early recognition is crucial, as delayed diagnosis may result in significant morbidity and mortality.
Case Presentation: We report the case of a 24-year-old previously healthy man admitted to the intensive care unit (ICU) with severe DRESS syndrome following carbamazepine exposure. Six weeks after initiation of treatment for newly diagnosed epilepsy, he developed high-grade fever, diffuse maculopapular rash, facial edema, cervical lymphadenopathy, and progressive respiratory distress. Laboratory investigations revealed marked eosinophilia (4.8 × 10⁹/L), atypical lymphocytosis, severe hepatitis (ALT 1,245 U/L; AST 987 U/L), acute kidney injury, and elevated inflammatory markers. Computed tomography demonstrated bilateral pulmonary infiltrates and generalized lymphadenopathy. The RegiSCAR score was 8, indicating definite DRESS syndrome.
Management and Outcome: Carbamazepine was immediately discontinued. The patient required ICU admission for acute hypoxemic respiratory failure and received systemic corticosteroids (methylprednisolone 1 mg/kg/day), supportive care, and close monitoring of organ dysfunction. Progressive clinical and biological improvement was observed, allowing discharge from the ICU after seven days and hospital discharge after three weeks. No relapse occurred during six months of follow-up.
Conclusion: This case highlights the importance of early recognition of DRESS syndrome and prompt withdrawal of the offending drug. Severe organ involvement may necessitate intensive care management, but favorable outcomes can be achieved with timely diagnosis and appropriate treatment.

KEYWORDS

DRESS syndrome; Carbamazepine; Eosinophilia; Intensive care; Severe cutaneous adverse reaction; Drug hypersensitivity.

REFERENCES

1) Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071-1080.
2) Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-611.
3) Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e1-693.e14.
4) Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68(5):709.e1-709.e9.
5) Chen YC, Cho YT, Chang CY, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a comprehensive review. J Clin Med. 2016;5(11):123.
6) Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588-597.
7) Criado PR, Criado RFJ, Avancini JM, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses and immune system. Isr Med Assoc J. 2012;14(9):577-582.
8) Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017;18(6):1243.
9) Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DIHS/DRESS): an update in 2019. Allergol Int. 2019;68(3):301-308.
10) Descamps V, Ben Saïd B, Sassolas B, et al. Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol. 2010;137(11):703-708.

Cite this article

Sebti, N. E. H., Haiba, Y. E., Sehbaoui, A., Chebbar, S., Mounir, A., & Bouhouri, M. (2026). Severe Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Requiring Intensive Care Management in A Young Adult: A Case Report. INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, 5(6), 567-570. https://doi.org/10.58806/ijhmr.2026.v5i6n10